Conjugates for the prevention or treatment of nicotine addiction

Disclosed is a hapten-carrier conjugate of formula III. The conjugate includes compounds such as trans-4-amino-N-(3-{ 5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl} propyl)cyclohexanecarboxamide and 4-mercapto-N-[2-({ 5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl} oxy)ethyl]butanamide which are conjug...

Full description

Saved in:
Bibliographic Details
Main Authors MEHELIC PAUL ROBERT, THORN JENNIFER MARIE, MERSON JAMES RICHARD, DAVIS HEATHER LYNN, PARSONS ERIN KRISTEN, MCCLUSKIE MICHAEL JOHN, GERVAIS DAVID P, KOLHE PARAG ASHOK, STEAD DAVID ROBERT, BROWN ALAN DANIEL, BHATTACHARYA KESHAB, ANASTASIOU NICKOLAS, FINNEMAN JARI ILMARI, JONES LYN HOWARD, PRYDE DAVID CAMERON
Format Patent
LanguageEnglish
Published 28.11.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Disclosed is a hapten-carrier conjugate of formula III. The conjugate includes compounds such as trans-4-amino-N-(3-{ 5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl} propyl)cyclohexanecarboxamide and 4-mercapto-N-[2-({ 5-[(2S)-1-methylpyrrolidin-2-yl]pyridin-3-yl} oxy)ethyl]butanamide which are conjugated to an optionally modified carrier protein selected from bacterial toxoids, immunogenic substances, viruses, virus-like particles, protein complexes, proteins, polypeptides, liposomes and immuno-stimulating complexes. The conjugates are useful for aiding smoking cessation in smokers.
Bibliography:Application Number: NZ20110603819